VistaGen Therapeutics, Inc.
VTGN · Healthcare · $13M
After-hours $0.300.00%
Price
$0.24
$0.30
Jul 1, 26Sep 29, 26
What's this stock's score right now?
See its score for free — revenue and money flow, graded on one standard.
Quarterly Financials
RevenueOperating IncomeNet Income
9/'26
Revenue$0M-79.7%
6/'26 vs prev quarter
Company Health
Market Cap$13M
Operating Margin-2784.3%
Among 326 Biotechnology peers
LowMedianHigh
PSR5.3xmedian 11.1xVistagen Reports Positive Findings Supporting Fasedienol's Potential in Very Severe Social Anxiety Disorder5d ago
Penny Stock Vistagen Analyst Highlights Caution after Anxiety Data6d ago
Vistagen Announces Preliminary Positive Data from Open-Label Extension Portion of PALISADE-4 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder7d ago
Vistagen to Present at Psych Congress 2026Sep 10
Vistagen Reports Fiscal Year 2027 First Quarter Financial Results and Corporate UpdateAug 14
Vistagen Announces Topline Results for Repeat Dose Study of Fasedienol for Acute Treatment of Social Anxiety DisorderAug 6
